# An assessment of an antioxidative status in patients with multiple sclerosis using standard biochemical analyses

## TL;DR

This study examined antioxidant levels in multiple sclerosis patients during relapse and remission to understand how they are affected by treatment and disease state.

## Contribution

The study provides new insights into how antioxidant levels vary with disease activity and treatment in multiple sclerosis patients.

## Key findings

- Antioxidant levels were found to differ between relapse and remission phases.
- Gender and treatment type influenced antioxidant levels in patients.
- Clinical characteristics like EDSS and relapse rate correlated with antioxidant status.

## Abstract

The study aimed to assess antioxidative status using standard biochemical analyses in multiple sclerosis patients during relapse and remission. Also, to evaluate the effects of gender, drug-modified treatment and clinical characteristics of multiple sclerosis on analyzed antioxidants.

The study consisted of 178 relapse-remitting multiple sclerosis patients (61 relapse/117 remission), 93 females and 85 males, with a mean age of 40.9±9.8 (average age of 40.9) and 80 matched healthy controls. Ongoing drug-modified treatment received 132 patients. The serum levels of uric acid, total bilirubin, albumin, and transferrin were analyzed in both patients and controls. Extended Disability Status Scale (EDSS), disease duration and annual relapse rate were used as clinical characteristics of multiple sclerosis.